<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 29 Sep 2024 14:08:50 +0000</lastbuilddate>
<pubDate>Sun, 29 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>New Guidelines and a focus on ischaemic heart disease, atrial fibrillation, innovative treatments of channelopathies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39342493/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 29;45(36):3299-3302. doi: 10.1093/eurheartj/ehae638.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39342493/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39342493</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae638>10.1093/eurheartj/ehae638</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39342493</guid>
<pubDate>Sun, 29 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-09-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>New Guidelines and a focus on ischaemic heart disease, atrial fibrillation, innovative treatments of channelopathies</dc:title>
<dc:identifier>pmid:39342493</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae638</dc:identifier>
</item>
<item>
<title>Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39340828/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The treatment benefits of the non-steroidal MRA finerenone were observed irrespective of concomitant use of an SGLT2i. These data suggest that the combined use of SGLT2i and a non-steroidal MRA may provide additive protection against cardiovascular events in patients with HF with mildly reduced or preserved ejection fraction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 28. doi: 10.1161/CIRCULATIONAHA.124.072055. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with heart failure (HF) with mildly reduced or preserved ejection fraction face heightened long-term risks of morbidity and mortality. The sodium glucose-co-transporter-2 inhibitors (SGLT2i) and the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone have both been shown to reduce the risk of cardiovascular events in this population, but the effects of their combined use are not known.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: FINEARTS-HF was a randomized, double-blind, placebo-controlled trial of finerenone in patients with HF and left ventricular ejection fraction (LVEF) ≥40%. Baseline SGLT2i use was a prespecified subgroup. The primary outcome was a composite of total (first and recurrent) worsening HF events and cardiovascular death. We first assessed for evidence of treatment heterogeneity based on baseline SGLT2i use. We further examined SGLT2i uptake during the trial and evaluated the treatment effects of finerenone accounting for baseline and during trial use of SGLT2i in time-varying analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 6,001 participants, 817 (13.6%) were treated with an SGLT2i at baseline. During 2.6-years median follow-up, treatment with finerenone similarly reduced the risk of the primary outcome in participants treated with an SGLT2i (rate ratio 0.83; 95% confidence interval 0.60 to 1.16) and without an SGLT2i at baseline (rate ratio 0.85; 95% confidence interval 0.74 to 0.98); P<sub>interaction</sub>=0.76. In follow-up, 980 participants initiated SGLT2i, which was less frequent in the finerenone arm compared with placebo (17.7% vs. 20.1%; hazard ratio 0.86; confidence interval 0.76 to 0.97). Time-updated analyses accounting for baseline and subsequent use of SGLT2i did not meaningfully alter the treatment effects of finerenone on the primary endpoint.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The treatment benefits of the non-steroidal MRA finerenone were observed irrespective of concomitant use of an SGLT2i. These data suggest that the combined use of SGLT2i and a non-steroidal MRA may provide additive protection against cardiovascular events in patients with HF with mildly reduced or preserved ejection fraction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39340828/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39340828</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072055>10.1161/CIRCULATIONAHA.124.072055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39340828</guid>
<pubDate>Sat, 28 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Ian J Kulac</dc:creator>
<dc:creator>Zi Michael Miao</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Meike Brinker</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Markus Florian Scheerer</dc:creator>
<dc:creator>Andrea Lage</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-09-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure</dc:title>
<dc:identifier>pmid:39340828</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072055</dc:identifier>
</item>
<item>
<title>Plea for an In-Depth Analysis of the RESHAPE-HF2 Results</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39340518/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 31:S0735-1097(24)08236-6. doi: 10.1016/j.jacc.2024.08.030. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39340518/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39340518</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.030>10.1016/j.jacc.2024.08.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39340518</guid>
<pubDate>Sat, 28 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jean-François Obadia</dc:creator>
<dc:creator>Xavier Armoiry</dc:creator>
<dc:creator>David Messika-Zeitoun</dc:creator>
<dc:creator>Jean-Noël Trochu</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:date>2024-09-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Plea for an In-Depth Analysis of the RESHAPE-HF2 Results</dc:title>
<dc:identifier>pmid:39340518</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.030</dc:identifier>
</item>
<item>
<title>CSF proteomics identifies early changes in autosomal dominant Alzheimer's disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39332414/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>In this high-throughput proteomic study of autosomal dominant Alzheimer's disease (ADAD), we sought to identify early biomarkers in cerebrospinal fluid (CSF) for disease monitoring and treatment strategies. We examined CSF proteins in 286 mutation carriers (MCs) and 177 non-carriers (NCs). The developed multi-layer regression model distinguished proteins with different pseudo-trajectories between these groups. We validated our findings with independent ADAD as well as sporadic AD datasets and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 19:S0092-8674(24)00978-4. doi: 10.1016/j.cell.2024.08.049. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In this high-throughput proteomic study of autosomal dominant Alzheimer's disease (ADAD), we sought to identify early biomarkers in cerebrospinal fluid (CSF) for disease monitoring and treatment strategies. We examined CSF proteins in 286 mutation carriers (MCs) and 177 non-carriers (NCs). The developed multi-layer regression model distinguished proteins with different pseudo-trajectories between these groups. We validated our findings with independent ADAD as well as sporadic AD datasets and employed machine learning to develop and validate predictive models. Our study identified 137 proteins with distinct trajectories between MCs and NCs, including eight that changed before traditional AD biomarkers. These proteins are grouped into three stages: early stage (stress response, glutamate metabolism, neuron mitochondrial damage), middle stage (neuronal death, apoptosis), and late presymptomatic stage (microglial changes, cell communication). The predictive model revealed a six-protein subset that more effectively differentiated MCs from NCs, compared with conventional biomarkers.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39332414/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39332414</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.049>10.1016/j.cell.2024.08.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39332414</guid>
<pubDate>Fri, 27 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yuanyuan Shen</dc:creator>
<dc:creator>Jigyasha Timsina</dc:creator>
<dc:creator>Gyujin Heo</dc:creator>
<dc:creator>Aleksandra Beric</dc:creator>
<dc:creator>Muhammad Ali</dc:creator>
<dc:creator>Ciyang Wang</dc:creator>
<dc:creator>Chengran Yang</dc:creator>
<dc:creator>Yueyao Wang</dc:creator>
<dc:creator>Daniel Western</dc:creator>
<dc:creator>Menghan Liu</dc:creator>
<dc:creator>Priyanka Gorijala</dc:creator>
<dc:creator>John Budde</dc:creator>
<dc:creator>Anh Do</dc:creator>
<dc:creator>Haiyan Liu</dc:creator>
<dc:creator>Brian Gordon</dc:creator>
<dc:creator>Jorge J Llibre-Guerra</dc:creator>
<dc:creator>Nelly Joseph-Mathurin</dc:creator>
<dc:creator>Richard J Perrin</dc:creator>
<dc:creator>Dario Maschi</dc:creator>
<dc:creator>Tony Wyss-Coray</dc:creator>
<dc:creator>Pau Pastor</dc:creator>
<dc:creator>Alan E Renton</dc:creator>
<dc:creator>Ezequiel I Surace</dc:creator>
<dc:creator>Erik C B Johnson</dc:creator>
<dc:creator>Allan I Levey</dc:creator>
<dc:creator>Ignacio Alvarez</dc:creator>
<dc:creator>Johannes Levin</dc:creator>
<dc:creator>John M Ringman</dc:creator>
<dc:creator>Ricardo Francisco Allegri</dc:creator>
<dc:creator>Nicholas Seyfried</dc:creator>
<dc:creator>Gregg S Day</dc:creator>
<dc:creator>Qisi Wu</dc:creator>
<dc:creator>M Victoria Fernández</dc:creator>
<dc:creator>Rawan Tarawneh</dc:creator>
<dc:creator>Eric McDade</dc:creator>
<dc:creator>John C Morris</dc:creator>
<dc:creator>Randall J Bateman</dc:creator>
<dc:creator>Alison Goate</dc:creator>
<dc:creator>Dominantly Inherited Alzheimer Network</dc:creator>
<dc:creator>Laura Ibanez</dc:creator>
<dc:creator>Yun Ju Sung</dc:creator>
<dc:creator>Carlos Cruchaga</dc:creator>
<dc:date>2024-09-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>CSF proteomics identifies early changes in autosomal dominant Alzheimer's disease</dc:title>
<dc:identifier>pmid:39332414</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.049</dc:identifier>
</item>
<item>
<title>Genomic surveillance as a scalable framework for precision phage therapy against antibiotic-resistant pathogens</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39332413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>Phage therapy is gaining increasing interest in the fight against critically antibiotic-resistant nosocomial pathogens. However, the narrow host range of bacteriophages hampers the development of broadly effective phage therapeutics and demands precision approaches. Here, we combine large-scale phylogeographic analysis with high-throughput phage typing to guide the development of precision phage cocktails targeting carbapenem-resistant Acinetobacter baumannii, a top-priority pathogen. Our...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 20:S0092-8674(24)01027-4. doi: 10.1016/j.cell.2024.09.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Phage therapy is gaining increasing interest in the fight against critically antibiotic-resistant nosocomial pathogens. However, the narrow host range of bacteriophages hampers the development of broadly effective phage therapeutics and demands precision approaches. Here, we combine large-scale phylogeographic analysis with high-throughput phage typing to guide the development of precision phage cocktails targeting carbapenem-resistant Acinetobacter baumannii, a top-priority pathogen. Our analysis reveals that a few strain types dominate infections in each world region, with their geographical distribution remaining stable within 6 years. As we demonstrate in Eastern Europe, this spatiotemporal distribution enables preemptive preparation of region-specific phage collections that target most local infections. Finally, we showcase the efficacy of phage cocktails against prevalent strain types using in vitro and animal infection models. Ultimately, genomic surveillance identifies patients benefiting from the same phages across geographical scales, thus providing a scalable framework for precision phage therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39332413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39332413</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.009>10.1016/j.cell.2024.09.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39332413</guid>
<pubDate>Fri, 27 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mihály Koncz</dc:creator>
<dc:creator>Tamás Stirling</dc:creator>
<dc:creator>Hiba Hadj Mehdi</dc:creator>
<dc:creator>Orsolya Méhi</dc:creator>
<dc:creator>Bálint Eszenyi</dc:creator>
<dc:creator>András Asbóth</dc:creator>
<dc:creator>Gábor Apjok</dc:creator>
<dc:creator>Ákos Tóth</dc:creator>
<dc:creator>László Orosz</dc:creator>
<dc:creator>Bálint Márk Vásárhelyi</dc:creator>
<dc:creator>Eszter Ari</dc:creator>
<dc:creator>Lejla Daruka</dc:creator>
<dc:creator>Tamás Ferenc Polgár</dc:creator>
<dc:creator>György Schneider</dc:creator>
<dc:creator>Sif Aldin Zalokh</dc:creator>
<dc:creator>Mónika Számel</dc:creator>
<dc:creator>Gergely Fekete</dc:creator>
<dc:creator>Balázs Bohár</dc:creator>
<dc:creator>Karolina Nagy Varga</dc:creator>
<dc:creator>Ádám Visnyovszki</dc:creator>
<dc:creator>Edit Székely</dc:creator>
<dc:creator>Monica-Sorina Licker</dc:creator>
<dc:creator>Oana Izmendi</dc:creator>
<dc:creator>Carmen Costache</dc:creator>
<dc:creator>Ina Gajic</dc:creator>
<dc:creator>Bojana Lukovic</dc:creator>
<dc:creator>Szabolcs Molnár</dc:creator>
<dc:creator>Uzonka Orsolya Szőcs-Gazdi</dc:creator>
<dc:creator>Csilla Bozai</dc:creator>
<dc:creator>Marina Indreas</dc:creator>
<dc:creator>Katalin Kristóf</dc:creator>
<dc:creator>Charles Van der Henst</dc:creator>
<dc:creator>Anke Breine</dc:creator>
<dc:creator>Csaba Pál</dc:creator>
<dc:creator>Balázs Papp</dc:creator>
<dc:creator>Bálint Kintses</dc:creator>
<dc:date>2024-09-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Genomic surveillance as a scalable framework for precision phage therapy against antibiotic-resistant pathogens</dc:title>
<dc:identifier>pmid:39332413</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.009</dc:identifier>
</item>
<item>
<title>mTOR activity paces human blastocyst stage developmental progression</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39332412/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>Many mammals can temporally uncouple conception from parturition by pacing down their development around the blastocyst stage. In mice, this dormant state is achieved by decreasing the activity of the growth-regulating mTOR signaling pathway. It is unknown whether this ability is conserved in mammals in general and in humans in particular. Here, we show that decreasing the activity of the mTOR signaling pathway induces human pluripotent stem cells (hPSCs) and blastoids to enter a dormant state...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 18:S0092-8674(24)00977-2. doi: 10.1016/j.cell.2024.08.048. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Many mammals can temporally uncouple conception from parturition by pacing down their development around the blastocyst stage. In mice, this dormant state is achieved by decreasing the activity of the growth-regulating mTOR signaling pathway. It is unknown whether this ability is conserved in mammals in general and in humans in particular. Here, we show that decreasing the activity of the mTOR signaling pathway induces human pluripotent stem cells (hPSCs) and blastoids to enter a dormant state with limited proliferation, developmental progression, and capacity to attach to endometrial cells. These in vitro assays show that, similar to other species, the ability to enter dormancy is active in human cells around the blastocyst stage and is reversible at both functional and molecular levels. The pacing of human blastocyst development has potential implications for reproductive therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39332412/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39332412</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.048>10.1016/j.cell.2024.08.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39332412</guid>
<pubDate>Fri, 27 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Dhanur P Iyer</dc:creator>
<dc:creator>Heidar Heidari Khoei</dc:creator>
<dc:creator>Vera A van der Weijden</dc:creator>
<dc:creator>Harunobu Kagawa</dc:creator>
<dc:creator>Saurabh J Pradhan</dc:creator>
<dc:creator>Maria Novatchkova</dc:creator>
<dc:creator>Afshan McCarthy</dc:creator>
<dc:creator>Teresa Rayon</dc:creator>
<dc:creator>Claire S Simon</dc:creator>
<dc:creator>Ilona Dunkel</dc:creator>
<dc:creator>Sissy E Wamaitha</dc:creator>
<dc:creator>Kay Elder</dc:creator>
<dc:creator>Phil Snell</dc:creator>
<dc:creator>Leila Christie</dc:creator>
<dc:creator>Edda G Schulz</dc:creator>
<dc:creator>Kathy K Niakan</dc:creator>
<dc:creator>Nicolas Rivron</dc:creator>
<dc:creator>Aydan Bulut-Karslioğlu</dc:creator>
<dc:date>2024-09-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>mTOR activity paces human blastocyst stage developmental progression</dc:title>
<dc:identifier>pmid:39332412</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.048</dc:identifier>
</item>
<item>
<title>Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39332395/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this prespecified secondary analysis of the FINEARTS-HF randomized clinical trial, long-term treatment with finerenone was estimated to extend event-free survival by up to 3 years among people with HF with mildly reduced or preserved ejection fraction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 27. doi: 10.1001/jamacardio.2024.3782. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: People living with heart failure (HF) with mildly reduced or preserved ejection fraction have substantially curtailed life expectancy free from clinical events compared with their peers of comparable age. The nonsteroidal mineralocorticoid receptor antagonist, finerenone, was recently shown to reduce risks of cardiovascular events in this population over a median follow-up of 2.6 years; as patients with HF typically continue treatment beyond this time frame, estimating the potential long-term benefits of finerenone could inform shared clinical decision-making.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To estimate the projected long-term treatment effects of finerenone in patients with HF with mildly reduced or preserved ejection fraction if treated over a patient's lifetime.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Prespecified analyses were conducted of the FINEARTS-HF trial, a phase 3 randomized clinical trial conducted across 653 sites in 37 countries. Adults 40 years and older with symptomatic HF and left ventricular ejection fraction of 40% or greater were randomized from September 2020 to January 2023. Median (IQR) follow-up was 2.6 (1.9-3.0) years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Finerenone (titrated to either 20 mg or 40 mg) or placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary composite outcome was time to cardiovascular death or worsening HF event. The long-term gains in survival free from a primary end point with finerenone were iteratively estimated with age-based Kaplan-Meier curves using age at randomization rather than time from randomization. Differences in areas under the survival curves between the finerenone and placebo arms represented event-free survival gains.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 6001 participants (median [IQR] age, 73 [66-79] years; 3269 male [54.5%]), mean survival free from the primary end point for a 55-year-old participant was 13.6 years (95% CI, 11.9-15.2 years) with finerenone and 10.5 years (95% CI, 6.8-11.3 years) with placebo, representing a gain in event-free survival of 3.1 years (95% CI, 0.8-5.4 years; P = .007). Mean event-free survival for a 65-year-old participant was 11.0 years (95% CI, 10.1-11.9 years) with finerenone and 8.9 years (95% CI, 8.1-9.8 years) with placebo, representing a gain of 2.0 years (95% CI, 0.8-3.3 years; P = .001). Projected mean event-free survival was numerically greater with finerenone than with placebo for every starting age between 50 to 80 years. Lifetime gains in event-free survival were observed even among individuals already treated with a sodium-glucose cotransporter 2 inhibitor (65-year-old participant: 3.1 years; 95% CI, 0.1-6.0 years; P = .04).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this prespecified secondary analysis of the FINEARTS-HF randomized clinical trial, long-term treatment with finerenone was estimated to extend event-free survival by up to 3 years among people with HF with mildly reduced or preserved ejection fraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39332395/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39332395</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3782>10.1001/jamacardio.2024.3782</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39332395</guid>
<pubDate>Fri, 27 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Maria Borentian</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Friederike U Behmenburg</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-09-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39332395</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3782</dc:identifier>
</item>
<item>
<title>Blunted Cardiac Mitophagy in Response to Metabolic Stress Contributes to HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39328167/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Maladaptation to metabolic stress in HFpEF hearts impairs mitochondrial quality control and contributed to the pathogenesis, which can be improved by stimulating fatty acid oxidation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 27. doi: 10.1161/CIRCRESAHA.123.324103. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Metabolic remodeling and mitochondrial dysfunction are hallmarks of heart failure with reduced ejection fraction. However, their role in the pathogenesis of HF with preserved ejection fraction (HFpEF) is poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a mouse model of HFpEF, induced by high-fat diet and Nω-nitrol-arginine methyl ester, cardiac energetics was measured by <sup>31</sup>P NMR spectroscopy and substrate oxidation profile was assessed by <sup>13</sup>C-isotopmer analysis. Mitochondrial functions were assessed in the heart tissue and human induced pluripotent stem cell-derived cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: HFpEF hearts presented a lower phosphocreatine content and a reduced phosphocreatine/ATP ratio, similar to that in heart failure with reduced ejection fraction. Decreased respiratory function and increased reactive oxygen species production were observed in mitochondria isolated from HFpEF hearts suggesting mitochondrial dysfunction. Cardiac substrate oxidation profile showed a high dependency on fatty acid oxidation in HFpEF hearts, which is the opposite of heart failure with reduced ejection fraction but similar to that in high-fat diet hearts. However, phosphocreatine/ATP ratio and mitochondrial function were sustained in the high-fat diet hearts. We found that mitophagy was activated in the high-fat diet heart but not in HFpEF hearts despite similar extent of obesity suggesting that mitochondrial quality control response was impaired in HFpEF hearts. Using a human induced pluripotent stem cell-derived cardiomyocyte mitophagy reporter, we found that fatty acid loading stimulated mitophagy, which was obliterated by inhibiting fatty acid oxidation. Enhancing fatty acid oxidation by deleting ACC2 (acetyl-CoA carboxylase 2) in the heart stimulated mitophagy and improved HFpEF phenotypes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Maladaptation to metabolic stress in HFpEF hearts impairs mitochondrial quality control and contributed to the pathogenesis, which can be improved by stimulating fatty acid oxidation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39328167/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39328167</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324103>10.1161/CIRCRESAHA.123.324103</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39328167</guid>
<pubDate>Fri, 27 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Akira Yoshii</dc:creator>
<dc:creator>Timothy S McMillen</dc:creator>
<dc:creator>Yajun Wang</dc:creator>
<dc:creator>Bo Zhou</dc:creator>
<dc:creator>Hongye Chen</dc:creator>
<dc:creator>Durba Banerjee</dc:creator>
<dc:creator>Melisa Herrero</dc:creator>
<dc:creator>Pei Wang</dc:creator>
<dc:creator>Naoto Muraoka</dc:creator>
<dc:creator>Wang Wang</dc:creator>
<dc:creator>Charles E Murry</dc:creator>
<dc:creator>Rong Tian</dc:creator>
<dc:date>2024-09-27</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Blunted Cardiac Mitophagy in Response to Metabolic Stress Contributes to HFpEF</dc:title>
<dc:identifier>pmid:39328167</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324103</dc:identifier>
</item>
<item>
<title>Visualizing Immune Checkpoint Inhibitors Derived Inflammation in Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39328090/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Accelerated atherosclerotic plaque inflammation triggered by anti-PD1 treatment can be noninvasively detected by 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-ECL1i PET. Aggravated plaque inflammation is time- and dose-dependent and predominately mediated by IFNγ signaling. This study warrants further investigation of CCR2 PET as a noninvasive approach to visualize atherosclerotic plaque inflammation and explore the underlying mechanism following ICI treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 27. doi: 10.1161/CIRCRESAHA.124.324260. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Immune checkpoint inhibitor (ICI) usage has resulted in immune-related adverse events in patients with cancer, such as accelerated atherosclerosis. Of immune cells involved in atherosclerosis, the role of CCR2+ (CC motif chemokine receptor 2-positive) proinflammatory macrophages is well documented. However, there is no noninvasive approach to determine the changes of these cells in vivo following ICI treatment and explore the underlying mechanisms of immune-related adverse events. Herein, we aim to use a CCR2 (CC motif chemokine receptor 2)-targeted radiotracer and positron emission tomography (PET) to assess the aggravated inflammatory response caused by ICI treatment in mouse atherosclerosis models and explore the mechanism of immune-related adverse events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: <i>Apoe</i><sup><i>-/-</i></sup> mice and <i>Ldlr</i><sup><i>-/-</i></sup> mice were treated with an ICI, anti-PD1 (programmed cell death protein 1) antibody, and compared with those injected with either isotype control IgG or saline. The radiotracer 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-ECL1i (extracellular loop 1 inverso) was used for PET imaging of CCR2+ macrophages. Atherosclerotic arteries were collected for molecular characterization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: CCR2 PET revealed significantly higher radiotracer uptake in both <i>Apoe</i><sup><i>-/-</i></sup> and <i>Ldlr</i><sup><i>-/-</i></sup> mice treated with anti-PD1 compared with the control groups. The increased expression of CCR2+ cells in <i>Apoe</i><sup><i>-/-</i></sup> and <i>Ldlr</i><sup><i>-/-</i></sup> mice was confirmed by immunostaining and flow cytometry. Single-cell RNA sequencing revealed elevated expression of CCR2 in myeloid cells. Mechanistically, IFNγ (interferon gamma) was essential for aggravated inflammation and atherosclerotic plaque progression following anti-PD1 treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Accelerated atherosclerotic plaque inflammation triggered by anti-PD1 treatment can be noninvasively detected by 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-ECL1i PET. Aggravated plaque inflammation is time- and dose-dependent and predominately mediated by IFNγ signaling. This study warrants further investigation of CCR2 PET as a noninvasive approach to visualize atherosclerotic plaque inflammation and explore the underlying mechanism following ICI treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39328090/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39328090</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324260>10.1161/CIRCRESAHA.124.324260</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39328090</guid>
<pubDate>Fri, 27 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Lanlan Lou</dc:creator>
<dc:creator>Lisa Detering</dc:creator>
<dc:creator>Hannah Luehmann</dc:creator>
<dc:creator>Junedh M Amrute</dc:creator>
<dc:creator>Deborah Sultan</dc:creator>
<dc:creator>Pan Ma</dc:creator>
<dc:creator>Alexandria Li</dc:creator>
<dc:creator>Divangana Lahad</dc:creator>
<dc:creator>Andreas Bredemeyer</dc:creator>
<dc:creator>Xiuli Zhang</dc:creator>
<dc:creator>Gyu Seong Heo</dc:creator>
<dc:creator>Kory Lavine</dc:creator>
<dc:creator>Yongjian Liu</dc:creator>
<dc:date>2024-09-27</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Visualizing Immune Checkpoint Inhibitors Derived Inflammation in Atherosclerosis</dc:title>
<dc:identifier>pmid:39328090</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324260</dc:identifier>
</item>
<item>
<title>Arg92Leu-cTnT Alters the cTnC-cTnI Interface Disrupting PKA-Mediated Relaxation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39328062/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These data show that the early diastolic dysfunction observed in a subset of HCM is attributable to allosterically mediated structural changes at the cTnC-cTnI interface that impair accessibility of PKA, thereby blunting β-adrenergic responsiveness and identifying a potential molecular target for therapeutic intervention.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 27. doi: 10.1161/CIRCRESAHA.124.325223. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Impaired left ventricular relaxation, high filling pressures, and dysregulation of Ca<sup>2+</sup> homeostasis are common findings contributing to diastolic dysfunction in hypertrophic cardiomyopathy (HCM). Studies have shown that impaired relaxation is an early observation in the sarcomere-gene-positive preclinical HCM cohort, which suggests the potential involvement of myofilament regulators in relaxation. A molecular-level understanding of mechanism(s) at the level of the myofilament is lacking. We hypothesized that mutation-specific, allosterically mediated, changes to the cTnC (cardiac troponin C)-cTnI (cardiac troponin I) interface can account for the development of early-onset diastolic dysfunction via decreased PKA accessibility to cTnI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: HCM mutations R92L-cTnT (cardiac troponin T; Arg92Leu) and Δ160E-cTnT (Glu160 deletion) were studied in vivo, in vitro, and in silico via 2-dimensional echocardiography, Western blotting, ex vivo hemodynamics, stopped-flow kinetics, time-resolved fluorescence resonance energy transfer, and molecular dynamics simulations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The HCM-causative mutations R92L-cTnT and Δ160E-cTnT result in different time-of-onset diastolic dysfunction. R92L-cTnT demonstrated early-onset diastolic dysfunction accompanied by a localized decrease in phosphorylation of cTnI. Constitutive phosphorylation of cTnI (cTnI-D<sub>23</sub>D<sub>24</sub>) was sufficient to recover diastolic function to non-Tg levels only for R92L-cTnT. Mutation-specific changes in Ca<sup>2+</sup> dissociation rates associated with R92L-cTnT reconstituted with cTnI-D<sub>23</sub>D<sub>24</sub> led us to investigate potential involvement of structural changes in the cTnC-cTnI interface as an explanation for these observations. We probed the interface via time-resolved fluorescence resonance energy transfer revealing a repositioning of the N-terminus of cTnI, closer to cTnC, and concomitant decreases in distance distributions at sites flanking the PKA consensus sequence. Implementing time-resolved fluorescence resonance energy transfer distances as constraints into our atomistic model identified additional electrostatic interactions at the consensus sequence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These data show that the early diastolic dysfunction observed in a subset of HCM is attributable to allosterically mediated structural changes at the cTnC-cTnI interface that impair accessibility of PKA, thereby blunting β-adrenergic responsiveness and identifying a potential molecular target for therapeutic intervention.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39328062/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39328062</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325223>10.1161/CIRCRESAHA.124.325223</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39328062</guid>
<pubDate>Fri, 27 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Melissa L Lynn</dc:creator>
<dc:creator>Jesus Jimenez</dc:creator>
<dc:creator>Romi L Castillo</dc:creator>
<dc:creator>Catherine Vasquez</dc:creator>
<dc:creator>Matthew M Klass</dc:creator>
<dc:creator>Anthony Baldo</dc:creator>
<dc:creator>Andrew Kim</dc:creator>
<dc:creator>Cyonna Gibson</dc:creator>
<dc:creator>Anne M Murphy</dc:creator>
<dc:creator>Jil C Tardiff</dc:creator>
<dc:date>2024-09-27</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Arg92Leu-cTnT Alters the cTnC-cTnI Interface Disrupting PKA-Mediated Relaxation</dc:title>
<dc:identifier>pmid:39328062</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325223</dc:identifier>
</item>
<item>
<title>Performance and Safety of the Extravascular Implantable Cardioverter-Defibrillator Through Long-Term Follow-Up: Final Results From the Pivotal Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39327797/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: From implant to study completion, the EV ICD Pivotal study demonstrated that a single integrated system with an extravascular lead placed in the substernal space maintains high ATP success, effective defibrillation, and a consistent safety profile.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 26. doi: 10.1161/CIRCULATIONAHA.124.071795. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Substernal lead placement of the extravascular implantable cardioverter-defibrillator (EV ICD) permits both defibrillation at thresholds similar to those seen with transvenous ICDs and effective antitachycardia pacing (ATP), while avoiding the vasculature and associated complications. The global Pivotal study has shown the EV ICD system to be safe and effective through 6 months, but long-term experience has yet to be published. We aim to report the performance and safety of the EV ICD system throughout the study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The EV ICD Pivotal study was a prospective, global, single-arm, pre-market clinical study. Individuals with a class I or IIa indication for a single-chamber ICD per guidelines were enrolled. Freedom from major system- or procedure-related complications, as well as appropriate and inappropriate therapy rates, were assessed through 3 years using the Kaplan-Meier method. Anti-tachycardia pacing success was calculated using simple proportions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: An implant was attempted in 316 patients [25.3% female, 53.8±13.1 years old, 81.6% primary prevention, LVEF 38.9%±15.4%]. Of 299 patients with a successful implant, 24 experienced 82 spontaneous arrhythmic episodes that were appropriately treated with either ATP only (38, 46.3%), shock only (34, 41.5%), or both (10, 12.2%) for a Kaplan-Meier-estimated rate of first any appropriate therapy of 9.2% at 3 years. Antitachycardia pacing was successful in 77.1% (37/48) of episodes, and ATP usage significantly increased from discharge to last follow-up visit (P&lt;0.0001). Shock therapy was successful in 100% (27/27) of discrete, spontaneous ventricular arrhythmias. The inappropriate shock rates at 1 and 3 years were 9.8% and 17.5%, respectively, with P-wave oversensing the predominant cause. No major intraprocedural complications were reported and the estimated freedom from system- or procedure-related major complications was 91.9% at 1 year and 89.0% at 3 years. The most common major complications were lead dislodgement (10 events; n=9 patients, 2.8%), postoperative wound or device pocket infection (n=8, 2.5%), and device inappropriate shock delivery (n=4, 1.3%). Twenty-four system revisions were performed as a result of major complications related to the EV ICD system or procedure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: From implant to study completion, the EV ICD Pivotal study demonstrated that a single integrated system with an extravascular lead placed in the substernal space maintains high ATP success, effective defibrillation, and a consistent safety profile.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39327797/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39327797</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071795>10.1161/CIRCULATIONAHA.124.071795</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39327797</guid>
<pubDate>Fri, 27 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Paul Friedman</dc:creator>
<dc:creator>Francis Murgatroyd</dc:creator>
<dc:creator>Lucas V A Boersma</dc:creator>
<dc:creator>Jaimie Manlucu</dc:creator>
<dc:creator>Bradley P Knight</dc:creator>
<dc:creator>Nicolas Clémenty</dc:creator>
<dc:creator>Christophe Leclercq</dc:creator>
<dc:creator>Anish Amin</dc:creator>
<dc:creator>Béla Merkely</dc:creator>
<dc:creator>Ulrika Birgersdotter-Green</dc:creator>
<dc:creator>Joseph Yat Sun Chan</dc:creator>
<dc:creator>Mauro Biffi</dc:creator>
<dc:creator>Reinoud Elwin Knops</dc:creator>
<dc:creator>Gregory Engel</dc:creator>
<dc:creator>Ignacio Muñoz Carvajal</dc:creator>
<dc:creator>Laurence M Epstein</dc:creator>
<dc:creator>Venkata Sagi</dc:creator>
<dc:creator>Jens Brock Johansen</dc:creator>
<dc:creator>Maciej Sterliński</dc:creator>
<dc:creator>Clemens Steinwender</dc:creator>
<dc:creator>Troy Hounshell</dc:creator>
<dc:creator>Richard Abben</dc:creator>
<dc:creator>Amy E Thompson</dc:creator>
<dc:creator>Yan Zhang</dc:creator>
<dc:creator>Christopher Wiggenhorn</dc:creator>
<dc:creator>Sarah Willey</dc:creator>
<dc:creator>Ian Crozier</dc:creator>
<dc:creator>Extravascular ICD Pivotal Study Investigators</dc:creator>
<dc:date>2024-09-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Performance and Safety of the Extravascular Implantable Cardioverter-Defibrillator Through Long-Term Follow-Up: Final Results From the Pivotal Study</dc:title>
<dc:identifier>pmid:39327797</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071795</dc:identifier>
</item>
<item>
<title>RETRACTED: GEDATOLISIB ASSOCIATED ACUTE MYOCARDITIS IN A PATIENT WITH BREAST CANCER</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39327001/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>The abstract "Gedatolisib Associated Acute Myocarditis in a Patient with Breast Adenocarcinoma" has been retracted at the request of the Editor-in-Chief because it was published before the completion of the clinical trial and full analysis of all data. There are no concerns about the findings as reported. This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13S):3575. doi: 10.1016/S0735-1097(24)05565-7. Epub 2024 Apr 5.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The abstract "Gedatolisib Associated Acute Myocarditis in a Patient with Breast Adenocarcinoma" has been retracted at the request of the Editor-in-Chief because it was published before the completion of the clinical trial and full analysis of all data. There are no concerns about the findings as reported. This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39327001/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39327001</a> | DOI:<a href=https://doi.org/10.1016/S0735-1097(24)05565-7>10.1016/S0735-1097(24)05565-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39327001</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Miles Shen</dc:creator>
<dc:creator>Mohamad Khattab</dc:creator>
<dc:creator>Emmanuel Akintoye</dc:creator>
<dc:creator>Lauren Anne Baldassarre</dc:creator>
<dc:creator>Jennifer Kwan</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>RETRACTED: GEDATOLISIB ASSOCIATED ACUTE MYOCARDITIS IN A PATIENT WITH BREAST CANCER</dc:title>
<dc:identifier>pmid:39327001</dc:identifier>
<dc:identifier>doi:10.1016/S0735-1097(24)05565-7</dc:identifier>
</item>
<item>
<title>Congenital heart defects in children born after assisted reproductive technology: a CoNARTaS study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39326528/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Assisted reproductive technology-conceived children have a higher prevalence of major CHDs, being rare, but severe conditions. The absolute risks are, however, modest and partly associated with multiple pregnancies, more prevalent in ART.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 26:ehae572. doi: 10.1093/eurheartj/ehae572. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Children born after assisted reproductive technology (ART) have worse perinatal outcomes compared with spontaneously conceived children. This study investigates whether children conceived after ART have a higher risk of congenital heart defects (CHDs) compared with children born after spontaneous conception (SC).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: All 7 747 637 liveborn children in Denmark (1994-2014), Finland (1990-2014), Norway (1984-2015), and Sweden (1987-2015), where 171 735 children were conceived after ART, were included. National ART and medical birth registry data were cross-linked with data from other health and population registries. Outcomes were major CHDs, severe CHDs, 6 hierarchical CHD lesion groups, and 10 selected major CHDs, diagnosed prenatally or up to 1 year of age (Denmark, Finland, and Sweden) and prenatally or at birth (Norway). The association between ART and CHDs was assessed with multivariable logistic regression analysis, with adjustment for available confounders.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Major CHDs were detected in 3159 children born after ART (1.84%) and in 86 824 children born after SC [1.15%; adjusted odds ratio (AOR) 1.36; 95% confidence interval (CI) 1.31-1.41]. Risk was highest in multiples, regardless of conception method. Severe CHDs were detected in 594 children born after ART (0.35%) and in 19 375 children born after SC (0.26%; AOR 1.30; 95% CI 1.20-1.42). Risk was similar between ICSI and IVF and between frozen and fresh embryo transfer.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Assisted reproductive technology-conceived children have a higher prevalence of major CHDs, being rare, but severe conditions. The absolute risks are, however, modest and partly associated with multiple pregnancies, more prevalent in ART.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39326528/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39326528</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae572>10.1093/eurheartj/ehae572</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39326528</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Nona Sargisian</dc:creator>
<dc:creator>Max Petzold</dc:creator>
<dc:creator>Eva Furenäs</dc:creator>
<dc:creator>Mika Gissler</dc:creator>
<dc:creator>Anne Lærke Spangmose</dc:creator>
<dc:creator>Sara Malchau Lauesgaard</dc:creator>
<dc:creator>Signe Opdahl</dc:creator>
<dc:creator>Anja Pinborg</dc:creator>
<dc:creator>Anna-Karina A Henningsen</dc:creator>
<dc:creator>Kjersti Westvik-Johari</dc:creator>
<dc:creator>Kristiina Rönö</dc:creator>
<dc:creator>Christina Bergh</dc:creator>
<dc:creator>Ulla-Britt Wennerholm</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Congenital heart defects in children born after assisted reproductive technology: a CoNARTaS study</dc:title>
<dc:identifier>pmid:39326528</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae572</dc:identifier>
</item>
<item>
<title>Assisted reproductive technology and heart defects: what's real and what's not?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39326508/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 26:ehae549. doi: 10.1093/eurheartj/ehae549. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39326508/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39326508</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae549>10.1093/eurheartj/ehae549</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39326508</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Nathalie Auger</dc:creator>
<dc:creator>Jessica Healy-Profitós</dc:creator>
<dc:creator>Shu Qin Wei</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Assisted reproductive technology and heart defects: what's real and what's not?</dc:title>
<dc:identifier>pmid:39326508</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae549</dc:identifier>
</item>
<item>
<title>Bronze Age cheese reveals human-Lactobacillus interactions over evolutionary history</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39326418/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>Despite the long history of consumption of fermented dairy, little is known about how the fermented microbes were utilized and evolved over human history. Here, by retrieving ancient DNA of Bronze Age kefir cheese (∼3,500 years ago) from the Xiaohe cemetery, we explored past human-microbial interactions. Although it was previously suggested that kefir was spread from the Northern Caucasus to Europe and other regions, we found an additional spreading route of kefir from Xinjiang to inland East...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 31:S0092-8674(24)00899-7. doi: 10.1016/j.cell.2024.08.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite the long history of consumption of fermented dairy, little is known about how the fermented microbes were utilized and evolved over human history. Here, by retrieving ancient DNA of Bronze Age kefir cheese (∼3,500 years ago) from the Xiaohe cemetery, we explored past human-microbial interactions. Although it was previously suggested that kefir was spread from the Northern Caucasus to Europe and other regions, we found an additional spreading route of kefir from Xinjiang to inland East Asia. Over evolutionary history, the East Asian strains gained multiple gene clusters with defensive roles against environmental stressors, which can be a result of the adaptation of Lactobacillus strains to various environmental niches and human selection. Overall, our results highlight the role of past human activities in shaping the evolution of human-related microbes, and such insights can, in turn, provide a better understanding of past human behaviors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39326418/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39326418</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.008>10.1016/j.cell.2024.08.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39326418</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yichen Liu</dc:creator>
<dc:creator>Bo Miao</dc:creator>
<dc:creator>Wenying Li</dc:creator>
<dc:creator>Xingjun Hu</dc:creator>
<dc:creator>Fan Bai</dc:creator>
<dc:creator>Yidilisi Abuduresule</dc:creator>
<dc:creator>Yalin Liu</dc:creator>
<dc:creator>Zequan Zheng</dc:creator>
<dc:creator>Wenjun Wang</dc:creator>
<dc:creator>Zehui Chen</dc:creator>
<dc:creator>Shilun Zhu</dc:creator>
<dc:creator>Xiaotian Feng</dc:creator>
<dc:creator>Peng Cao</dc:creator>
<dc:creator>Wanjing Ping</dc:creator>
<dc:creator>Ruowei Yang</dc:creator>
<dc:creator>Qingyan Dai</dc:creator>
<dc:creator>Feng Liu</dc:creator>
<dc:creator>Chan Tian</dc:creator>
<dc:creator>Yimin Yang</dc:creator>
<dc:creator>Qiaomei Fu</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Bronze Age cheese reveals human-Lactobacillus interactions over evolutionary history</dc:title>
<dc:identifier>pmid:39326418</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.008</dc:identifier>
</item>
<item>
<title>Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39326417/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>We report the 1-year results from one patient as the preliminary analysis of a first-in-human phase I clinical trial (ChiCTR2300072200) assessing the feasibility of autologous transplantation of chemically induced pluripotent stem-cell-derived islets (CiPSC islets) beneath the abdominal anterior rectus sheath for type 1 diabetes treatment. The patient achieved sustained insulin independence starting 75 days post-transplantation. The patient's time-in-target glycemic range increased from a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 20:S0092-8674(24)01022-5. doi: 10.1016/j.cell.2024.09.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">We report the 1-year results from one patient as the preliminary analysis of a first-in-human phase I clinical trial (ChiCTR2300072200) assessing the feasibility of autologous transplantation of chemically induced pluripotent stem-cell-derived islets (CiPSC islets) beneath the abdominal anterior rectus sheath for type 1 diabetes treatment. The patient achieved sustained insulin independence starting 75 days post-transplantation. The patient's time-in-target glycemic range increased from a baseline value of 43.18% to 96.21% by month 4 post-transplantation, accompanied by a decrease in glycated hemoglobin, an indicator of long-term systemic glucose levels at a non-diabetic level. Thereafter, the patient presented a state of stable glycemic control, with time-in-target glycemic range at >;98% and glycated hemoglobin at around 5%. At 1 year, the clinical data met all study endpoints with no indication of transplant-related abnormalities. Promising results from this patient suggest that further clinical studies assessing CiPSC-islet transplantation in type 1 diabetes are warranted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39326417/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39326417</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.004>10.1016/j.cell.2024.09.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39326417</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Shusen Wang</dc:creator>
<dc:creator>Yuanyuan Du</dc:creator>
<dc:creator>Boya Zhang</dc:creator>
<dc:creator>Gaofan Meng</dc:creator>
<dc:creator>Zewen Liu</dc:creator>
<dc:creator>Soon Yi Liew</dc:creator>
<dc:creator>Rui Liang</dc:creator>
<dc:creator>Zhengyuan Zhang</dc:creator>
<dc:creator>Xiangheng Cai</dc:creator>
<dc:creator>Shuangshuang Wu</dc:creator>
<dc:creator>Wei Gao</dc:creator>
<dc:creator>Dewei Zhuang</dc:creator>
<dc:creator>Jiaqi Zou</dc:creator>
<dc:creator>Hui Huang</dc:creator>
<dc:creator>Mingyang Wang</dc:creator>
<dc:creator>Xiaofeng Wang</dc:creator>
<dc:creator>Xuelian Wang</dc:creator>
<dc:creator>Ting Liang</dc:creator>
<dc:creator>Tengli Liu</dc:creator>
<dc:creator>Jiabin Gu</dc:creator>
<dc:creator>Na Liu</dc:creator>
<dc:creator>Yanling Wei</dc:creator>
<dc:creator>Xuejie Ding</dc:creator>
<dc:creator>Yue Pu</dc:creator>
<dc:creator>Yixiang Zhan</dc:creator>
<dc:creator>Yu Luo</dc:creator>
<dc:creator>Peng Sun</dc:creator>
<dc:creator>Shuangshuang Xie</dc:creator>
<dc:creator>Jiuxia Yang</dc:creator>
<dc:creator>Yiqi Weng</dc:creator>
<dc:creator>Chunlei Zhou</dc:creator>
<dc:creator>Zhenglu Wang</dc:creator>
<dc:creator>Shuang Wang</dc:creator>
<dc:creator>Hongkui Deng</dc:creator>
<dc:creator>Zhongyang Shen</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient</dc:title>
<dc:identifier>pmid:39326417</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.004</dc:identifier>
</item>
<item>
<title>Saturation mutagenesis-reinforced functional assays for disease-related genes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39326416/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>Interpretation of disease-causing genetic variants remains a challenge in human genetics. Current costs and complexity of deep mutational scanning methods are obstacles for achieving genome-wide resolution of variants in disease-related genes. Our framework, saturation mutagenesis-reinforced functional assays (SMuRF), offers simple and cost-effective saturation mutagenesis paired with streamlined functional assays to enhance the interpretation of unresolved variants. Applying SMuRF to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 19:S0092-8674(24)00976-0. doi: 10.1016/j.cell.2024.08.047. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Interpretation of disease-causing genetic variants remains a challenge in human genetics. Current costs and complexity of deep mutational scanning methods are obstacles for achieving genome-wide resolution of variants in disease-related genes. Our framework, saturation mutagenesis-reinforced functional assays (SMuRF), offers simple and cost-effective saturation mutagenesis paired with streamlined functional assays to enhance the interpretation of unresolved variants. Applying SMuRF to neuromuscular disease genes FKRP and LARGE1, we generated functional scores for all possible coding single-nucleotide variants, which aid in resolving clinically reported variants of uncertain significance. SMuRF also demonstrates utility in predicting disease severity, resolving critical structural regions, and providing training datasets for the development of computational predictors. Overall, our approach enables variant-to-function insights for disease genes in a cost-effective manner that can be broadly implemented by standard research laboratories.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39326416/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39326416</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.047>10.1016/j.cell.2024.08.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39326416</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Kaiyue Ma</dc:creator>
<dc:creator>Shushu Huang</dc:creator>
<dc:creator>Kenneth K Ng</dc:creator>
<dc:creator>Nicole J Lake</dc:creator>
<dc:creator>Soumya Joseph</dc:creator>
<dc:creator>Jenny Xu</dc:creator>
<dc:creator>Angela Lek</dc:creator>
<dc:creator>Lin Ge</dc:creator>
<dc:creator>Keryn G Woodman</dc:creator>
<dc:creator>Katherine E Koczwara</dc:creator>
<dc:creator>Justin Cohen</dc:creator>
<dc:creator>Vincent Ho</dc:creator>
<dc:creator>Christine L O'Connor</dc:creator>
<dc:creator>Melinda A Brindley</dc:creator>
<dc:creator>Kevin P Campbell</dc:creator>
<dc:creator>Monkol Lek</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Saturation mutagenesis-reinforced functional assays for disease-related genes</dc:title>
<dc:identifier>pmid:39326416</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.047</dc:identifier>
</item>
<item>
<title>Mechanisms of long COVID and the path toward therapeutics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39326415/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>Long COVID, a type of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC) defined by medically unexplained symptoms following infection with SARS-CoV-2, is a newly recognized infection-associated chronic condition that causes disability in some people. Substantial progress has been made in defining its epidemiology, biology, and pathophysiology. However, there is no cure for the tens of millions of people believed to be experiencing long COVID, and industry...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 25:S0092-8674(24)00886-9. doi: 10.1016/j.cell.2024.07.054. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Long COVID, a type of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC) defined by medically unexplained symptoms following infection with SARS-CoV-2, is a newly recognized infection-associated chronic condition that causes disability in some people. Substantial progress has been made in defining its epidemiology, biology, and pathophysiology. However, there is no cure for the tens of millions of people believed to be experiencing long COVID, and industry engagement in developing therapeutics has been limited. Here, we review the current state of knowledge regarding the biology and pathophysiology of long COVID, focusing on how the proposed mechanisms explain the physiology of the syndrome and how they provide a rationale for the implementation of a broad experimental medicine and clinical trials agenda. Progress toward preventing and curing long COVID and other infection-associated chronic conditions will require deep and sustained investment by funders and industry.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39326415/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39326415</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.054>10.1016/j.cell.2024.07.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39326415</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael J Peluso</dc:creator>
<dc:creator>Steven G Deeks</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mechanisms of long COVID and the path toward therapeutics</dc:title>
<dc:identifier>pmid:39326415</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.054</dc:identifier>
</item>
<item>
<title>Metabolic and Shear Stress Regulate Endothelial Epas1 in Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39325850/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 27;135(8):838-840. doi: 10.1161/CIRCRESAHA.124.325131. Epub 2024 Sep 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39325850/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39325850</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325131>10.1161/CIRCRESAHA.124.325131</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39325850</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith C Sluimer</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Metabolic and Shear Stress Regulate Endothelial Epas1 in Atherosclerosis</dc:title>
<dc:identifier>pmid:39325850</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325131</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39325848/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 27;135(8):804-805. doi: 10.1161/RES.0000000000000694. Epub 2024 Sep 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39325848/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39325848</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000694>10.1161/RES.0000000000000694</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39325848</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:date>2024-09-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:39325848</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000694</dc:identifier>
</item>
<item>
<title>Deconstructing Regenerative Medicine: From Mechanistic Studies of Cell Therapy to Novel Bioinspired RNA Drugs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39325847/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240929100849&amp;v=2.18.0.post9+e462414
      <description>All Food and Drug Administration-approved noncoding RNA (ncRNA) drugs (n≈20) target known disease-causing molecular pathways by mechanisms such as antisense. In a fortuitous evolution of work on regenerative medicine, my coworkers and I inverted the RNA drug discovery process: first we identified natural disease-modifying ncRNAs, then used them as templates for new synthetic RNA drugs. Mechanism was probed only after bioactivity had been demonstrated. The journey began with the development of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 27;135(8):877-885. doi: 10.1161/CIRCRESAHA.124.323058. Epub 2024 Sep 26.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">All Food and Drug Administration-approved noncoding RNA (ncRNA) drugs (n≈20) target known disease-causing molecular pathways by mechanisms such as antisense. In a fortuitous evolution of work on regenerative medicine, my coworkers and I inverted the RNA drug discovery process: first we identified natural disease-modifying ncRNAs, then used them as templates for new synthetic RNA drugs. Mechanism was probed only after bioactivity had been demonstrated. The journey began with the development of cardiosphere-derived cells (CDCs) for cardiac regeneration. While testing CDCs in a first-in-human trial, we discovered they worked indirectly: ncRNAs within CDC-secreted extracellular vesicles mediate the therapeutic benefits. The vast majority of such ncRNAs are fragments of unknown function. We chose several abundant ncRNA species from CDC-secreted extracellular vesicles, synthesized and screened each of them in vitro and in vivo. Those with exceptional disease-modifying bioactivity inspired new chemical entities that conform to the structural conventions of the Food and Drug Administration-approved ncRNA armamentarium. This discovery arc-Cell-Derived RNA from Extracellular vesicles for bioinspired Drug develOpment, or CREDO-has yielded various promising lead compounds, each of which works via a unique, and often novel, mechanism. The process relies on emergent insights to shape therapeutic development. The initial focus of our inquiry-CDCs-are now themselves in phase 3 testing for Duchenne muscular dystrophy and its associated cardiomyopathy. But the intravenous delivery strategy and the repetitive dosing protocol for CDCs, which have proven key to clinical success, both arose from systematic mechanistic inquiry. Meanwhile, emergent insights have led to multiple cell-free therapeutic candidates: CDC-secreted extracellular vesicles are in preclinical development for ventricular arrhythmias, while the CREDO-conceived RNA drugs are in translation for diseases ranging from myocarditis to scleroderma.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39325847/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240929100849&v=2.18.0.post9+e462414">39325847</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.323058>10.1161/CIRCRESAHA.124.323058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39325847</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Eduardo Marbán</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Deconstructing Regenerative Medicine: From Mechanistic Studies of Cell Therapy to Novel Bioinspired RNA Drugs</dc:title>
<dc:identifier>pmid:39325847</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.323058</dc:identifier>
</item>





























</channel>
</rss>